Trial reportJournal of gastroenterology2005
Treatment of Crohn's disease with anti-IL-6 receptor antibody.
Trial report in Journal of gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 58 citations in OpenAlex.
- Exploring the therapeutic potential of interleukin-6 receptor blockade in autoimmune diseases using drug target mendelian randomization.Immunogenetics · 2024Article
- Berberine-loaded PLGA nanoparticles alleviate ulcerative colitis by targeting IL-6/IL-6R axis.Journal of translational medicine · 2024Article
- Article
- Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiome.Journal of cell communication and signaling · 2023Review
- Article
- Cytoskeletal Organization and Cell Polarity in the Pathogenesis of Crohn's Disease.Clinical reviews in allergy & immunology · 2021Review
- Deletion of IL-6 Exacerbates Colitis and Induces Systemic Inflammation in IL-10-Deficient Mice.Journal of Crohn's & colitis · 2020Article
- Article
- A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease.Journal of immunology research · 2019Review
- Human Gut-Associated Natural Killer Cells in Health and Disease.Frontiers in immunology · 2019Review
- Absence of specific alternatively spliced exon of CD44 in macrophages prevents colitis.Mucosal immunology · 2018Article
- Chronic stress promotes colitis by disturbing the gut microbiota and triggering immune system response.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- A functional genomics predictive network model identifies regulators of inflammatory bowel disease.Nature genetics · 2017Article
- Growth Hormone Resistance-Special Focus on Inflammatory Bowel Disease.International journal of molecular sciences · 2017Review
- Screening of an anti-inflammatory peptide from Hydrophis cyanocinctus and analysis of its activities and mechanism in DSS-induced acute colitis.Scientific reports · 2016Article
- Article
- Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway activation of claudin-2 gene.PloS one · 2014Article
- Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor.Anti-cancer agents in medicinal chemistry · 2012Review
- New pathophysiological insights and modern treatment of IBD.Journal of gastroenterology · 2010Review
- Campylobacter jejuni drives MyD88-independent interleukin-6 secretion via Toll-like receptor 2.Infection and immunity · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have demonstrated, by using a T-cell transfer murine colitis model, that blocking interleukin 6 (IL-6) signaling with monoclonal antibody (mAb) to IL-6 receptor (IL-6R) abrogated apoptosis resistance of lamina propria T cells, suppressed the expression of vascular adhesion molecules, and successfully prevented and treated intestinal inflammation. Based on these results, we carried out an exploratory clinical trial to investigate the safety and efficacy of humanized anti-IL-6R mAb, MRA, in patients with Crohn's disease (CD). The results were promising, with 80% of the patients given every-2-week MRA infusions for 12 weeks showing a significantly higher clinical response rate as compared to 31% of the placebo-treated patients. Twenty percent of the patients on this regimen went into remission as compared to 0% of the placebo group. The acute-phase responses were normalized by a single MRA infusion, which strongly suggests IL-6 is the major cytokine responsible for their production in CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.